Today Chemotrade looks back onto the history of the company.
Chemotrade was founded in 1992 in Düsseldorf, focusing on the distribution of Radioisotopes and Stable Isotope. Based on the profound market knowledge of its founders and employees, the company quickly developed into a household name within the market for isotopes.
At the beginning, Chemotrade focused on supplying Isotopes made in Russia in bulk, but to strengthen its market position, the company acquired Isocommerz. This new acquisition manifested itself in the companies’ subsidiary - Chemotrade Leipzig.
Isonics Corporation takeover of Chemotrade Düsseldorf in 1998 resulted in the division of Chemotrade Leipzig in 2002.
In 2006, Chemotrade Leipzig and Düsseldorf merged again allowing the company to maintain its expertise and making it a significant player in the market of Isotopes for more than 25 years.
The development of our radioactive isotopes business has been very positive and therefore has required our entire attention. Consequently in 2010 we decided to manage all business activities from Düsseldorf & stopped the distribution of “light isotopes” (except 15-N) resulting in the closure of our Leipzig offices.
Since 2013 we belong to Eckert & Ziegler* Group, with around 800 employees one of the world’s largest providers of isotope-related components for radiotherapy and nuclear medicine.
(1) These “General Business and Delivery Terms and Conditions of Eckert & Ziegler Chemotrade GmbH” (hereinafter referred to as “Terms and Conditions”) are a direct component of the contractual agreements concluded between the Eckert & Ziegler Chemotrade GmbH (hereinafter referred to as “the Company”) and the customers regarding our services. Unless otherwise agreed, all offers, acceptances and services are conducted exclusively on the basis of these Terms and Conditions. Within the framework of an existing business relationship with the customer, the Terms and Conditions are also part of the agreement even if the Company does not once again expressly make reference to their inclusion.
(2) The following applies to existing agreements: The customer will be notified in writing of amendments to these Terms and Conditions. If the customer agreed to correspond with the Company via an electronic communication channel within the framework of the business relationship, the amendments may also be communicated in this way, if the type of communication allows the customer to save or print out the amendments in a readable format. They are considered approved if the customer does not object in writing or in any other agreed electronic mode of communication. The notification will include explicit reference to this consequence. The customer must send the objection to the Company within six (6) weeks of the notification of amendment.
(3) Deviating terms and conditions of the customer are hereby objected to; these are also not deemed to be accepted during execution of the agreement. Sentence 1 also applies to possible provisions on contractual penalties. Other agreements, in particular guarantees, amendments and supplementary agreements, only take effect if the Company expressly agrees to such.
Updated: June 2021
Eckert & Ziegler Chemotrade GmbH
Commercial register: HRB 62811
Competent Court: Amtsgericht Düsseldorf/Germany
Phone: 0211-62 60 62
Fax: 0211-62 60 68
The security of your personal data is important to us. The principles for the processing of personal data according to the General Data Protection Regulation (GDPR): Transparency, legality, purpose limitation, data accuracy and data minimization are also standards for the handling of your data. We attach great importance to justifying the trust you have placed in us in this regard as well. We therefore protect your personal data in particular against access by unauthorized persons.
The intensity of the collection, processing and use of your data depends on how you use our services. By visiting our website you agree that we may collect, process, use and store your individual personal data to the extent indicated below. Confidential handling of this data is a matter of course for us. The data protection declaration is continuously revised and adapted. The current status of the declaration is May 2018.
When you visit our website, certain data are automatically collected in anonymized form. These are, in particular, data about
All of these data are collected by us for analysis purposes. They will be evaluated to improve our website and service. The individual data in each case cannot be assigned to a specific person. The data mentioned are primarily device-related. However, it may be possible to associate them with specific people in connection with other data. We use the data collected for statistical purposes, to evaluate the attractiveness of our offers, to evaluate user behavior in order to improve and expand our range of services and to identify errors and optimize processes. Data are only linked as far as necessary for the purposes mentioned.
The data stored by us will be deleted as soon as they are no longer needed for the purposes stated herein. The data will be deleted after completion of the specified purposes, if they are not, or will not be, stored for documentation purposes (e.g., due to existing retention periods)
Insofar as we obtain consent for the processing of your personal data, Art. 6 para. 1 lit. a) DSGVO serves as the legal basis for data processing.
Insofar as your personal data are processed because this is necessary for the fulfillment of a contract or within the framework of a contract-like relationship with you, Art. 6 para. 1 lit. b) DSGVO serves as the legal basis for data processing.
Insofar as we process your personal data to fulfill a legal obligation, Art. 6 para. 1 lit. c) DSGVO serves as the legal basis for data processing.
Art. 6 para. 1 lit. f) DSGVO may also be used as a legal basis for data processing if the processing of your personal data is necessary to safeguard a legitimate interest of our company or a third party and your interests, fundamental rights and freedoms do not require the protection of personal data.
Within the framework of this data protection declaration, we always point out the legal basis on which we base the processing of your personal data.
We attach great importance to explaining the processing of your personal data as transparently as possible and also to inform you about the rights to which you are entitled. If you require further information or wish to exercise the rights to which you are entitled, you can contact us at any time, so that we can take care of your request.
You have extensive rights regarding the processing of your personal data. First of all, you have a comprehensive right to information and you can request the correction and/or deletion or blocking of your personal data if necessary. You may also demand a limitation of the processing and have a right of objection. You also have a right to data transferability with regard to the personal data you have provided to us.
If you wish to assert any of your rights and/or receive further information, please contact our customer service. Alternatively, you can also contact our data protection officer.
Once you have given your consent, it can be freely revoked at any time with effect for the future. The revocation of consent shall not affect the legality of the processing carried out on the basis of the consent until revocation. The contact person for this is also our customer service is our data protection officer.
If the processing of your personal data is not based on consent, but on another legal basis, you can object to this data processing. Your objection will lead to a review and, if necessary, termination of data processing. You will be informed of the results of the review and - if data processing is nevertheless to be continued - we will provide you with more detailed information as to why data processing is permissible.
We would like to point out that we continue to store personal data even after the conclusion of a business relationship. We can only delete personal data if there are no legal retention periods to the contrary. Only after expiry of the retention periods can we comply with a request for deletion if necessary. If you wish the data to be deleted during the retention period, we will block the personal data for use until the expiry of the retention period and will no longer use it in this respect.
If you use our option to contact us (www.chemotrade.de/contact ), personal data will be collected and stored. The correspondence itself, including the associated personal data (first name, last name, company, e-mail address, etc.) that you provide will be stored accordingly. These data are used only to carry out the correspondence. After the correspondence has been completed, the personal data and the contents of the correspondence are stored for documentation purposes, in order to have the capability, in case of further queries or in similar cases, of establishing a uniform service practice. Of course, the personal data obtained in this context will not be disclosed to unauthorized third parties.
Children and adolescents under the age of 18 should not submit any personal information to us without the consent of their parent or legal guardian.
Eckert & Ziegler Chemotrade GmbH
You have the right to report alleged violations of privacy legislation and to complain to the relevant regulatory body. The complaint can be sent to:
Landesbeauftragte für Datenschutz und Informationsfreiheit Nordrhein-Westfalen [Commissioner for Data Protection and Freedom of Information]
40213 Düsseldorf, Germany
Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application
Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brasil
Eckert & Ziegler Announces Clinical Trial Notification for Joint Clinical Trial in Japan
Eckert & Ziegler: One-Off Effects and Robust Operating Business Push Nine-Month Result to Record Level
Eckert & Ziegler Acquires Property for Radiopharmaceutical Production Site in China
Eckert & Ziegler Acquires 53,000 Square Feet Facility for Expansion of Contract Development and Manufacturing Services
Nantes University Hospital Doses First Patients with Eckert & Ziegler's Novel Ga-68 Imaging Agent PENTIXAFOR
Eckert & Ziegler Starts Technetium-99 Delivery in Brazil
Eckert & Ziegler with Strong First Half of 2021
Eckert & Ziegler Receives Manufacturing Authorization for Thorium and Lutetium Compounds
Eckert & Ziegler Takes over Brazilian Isotope Specialists - Strengthening their Presence in South America
27-07-2021, 17:27 CEST (Ad hoc press release)
Half Year Results Stronger than Expected; Eckert & Ziegler Increases Profit Forecast by approximately 20%
Eckert & Ziegler: Affiliate Receives Additional NIAID Funding to Advance Pharmaceutical Development
Eckert & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for Prostate Cancer Diagnostic in the United States
Eckert & Ziegler Granted Exclusive Distribution Rights by Telix Pharmaceuticals for Prostate Cancer Diagnostic
Eckert & Ziegler: Record Income Due to Sale of Division and Strong Core Business
Eckert & Ziegler Signs Long-Term Supply Agreement with Sirtex Medical on Yttrium-90 for Treating Liver Cancer
16-04-2021, 11:01 CEST (Ad hoc press release)
Eckert & Ziegler Acquires Direct Majority Stake in Drug Developer PENTIXAPHARM
Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in Berlin
12-04-2021, 21:12 CEST (Ad hoc press release)
Eckert & Ziegler Receives Technetium Generator Licenses for Brazil
25-03-2021, 19:52 CET (Ad hoc press release)
Eckert & Ziegler: Dividend Proposal EUR 0.45 per Share. Profit Increase in 2020. Positive Outlook for 2021.
24-03-2021, 14:09 CET (Ad hoc press release)
Eckert & Ziegler Divests From Tumour Irradiation Business
17-03-2021, 23:49 CET (Ad hoc press release)
Eckert & Ziegler 2020: Earnings higher than expected
Eckert & Ziegler to Start Development of Radioisotope Production Facility in Jintan, PR China
Eckert & Ziegler Wins Again Award for Excellent Training Quality
Eckert & Ziegler Wins Order for Hot Cell Construction from Dutch Research Center
04-02-2021, 19:28 CET (Ad hoc press release)
Eckert & Ziegler: PENTIXAPHARM Lead Candidate PENTIXAFOR Can Go in Phase III Study, EMA says
Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in USA
Eckert & Ziegler: Seed Implantation for Prostate Cancer Receives Reimbursement for Outpatient Care